Join
Live feed
·
PRReleasevia Quantisnow
Estrella Immunopharma Inc. logo

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
ESLA· Estrella Immunopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ESLA (Estrella Immunopharma Inc.) and more on Quantisnow.